Barriers and facilitators to pre-exposure prophylaxis among African migrants in high income countries: a systematic review
Chido Mwaturura
A B H , Michael Traeger C D , Christopher Lemoh E , Mark Stoove C D , Brian Price A , Alison Coelho F , Masha Mikola F , Kathleen E. Ryan A D and Edwina Wright A D G
+ Author Affiliations
- Author Affiliations
A Department of Infectious Diseases, The Alfred and Central Clinical School, Monash University, Melbourne, Vic., Australia.
B Melbourne Medical School, University of Melbourne, Melbourne, Vic., Australia.
C School of Public Health and Preventative Medicine, Monash University, Melbourne, Vic., Australia.
D Burnet Institute, Melbourne, Vic., Australia.
E Monash Infectious Diseases, Monash Health, Melbourne, Vic., Australia.
F Centre for Culture, Ethnicity & Health, Melbourne, Vic., Australia.
G Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Vic., Australia.
H Corresponding author. Email: chido.mwaturura@gmail.com
Sexual Health 18(2) 130-139 https://doi.org/10.1071/SH20175
Submitted: 21 September 2020 Accepted: 8 December 2020 Published: 4 March 2021
Journal Compilation © CSIRO 2021 Open Access CC BY-NC
Abstract
Background: The aim of this review is to explore acceptability, barriers, and facilitators to PrEP use among African migrants in high-income countries. Methods: A systematic review was conducted to explore reasons that contribute to low PrEP uptake in this population. Three online databases, abstracts from key conferences and reference lists of relevant studies articles published between the 2 July 2018 and 3 March 2019 were searched. Narrative synthesis was performed on quantitative data and thematic synthesis was performed on qualitative data. Results: Of 1779 titles retrieved, two cross-sectional studies (United States (US) (n = 1), United Kingdom (UK) (n = 1)) and six qualitative studies (US (n = 2), UK (n = 3), Australia (n = 1)) met inclusion criteria. PrEP acceptability was reported in one cross-sectional article and two qualitative articles. Cross-sectional studies measured acceptability and willingness to use PrEP; in one study, 46% of African migrant men found PrEP use acceptable, and following PrEP education, another study categorised 60% of participants as willing to use PrEP if it were cost-free. Qualitative studies reported mixed acceptability, with higher acceptability reported for serodiscordant couples. Barriers and facilitators to PrEP use were coded into five themes: cultural aspects of stigma; knowledge gap in health literacy; risks unrelated to HIV transmission; practical considerations for PrEP use; and the impact of PrEP use on serodiscordant couples. Conclusions: Several common barriers to PrEP use, including stigma, health literacy and risk perception and cost, were identified. Findings were limited by there being no published data on uptake. Additional work is needed to understand PrEP acceptability and uptake among African migrants.
Keywords: acceptability, Africa, barriers, facilitators, HIV, migrant, PrEP, willingness.
References
[1] World Health Organization. Guidance on Pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men who have sex with men and transgender women at high risk of HIV in implementation research: recommendations for use in the context of demonstration projects. Geneva: World Health Organization; 2012.[2] Vaccine Advocacy Coalition AIDS. PrEPWatch. New York: AVAC; 2018 [updated 31 Dec 2018. Available online at: https://www.prepwatch.org/country/australia/.
[3] Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14 820–9.
| Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.Crossref | GoogleScholarGoogle Scholar | 25065857PubMed |
[4] Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis 2014; 60 804–10.
| Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 25409469PubMed |
[5] Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381 2083–90.
| Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.Crossref | GoogleScholarGoogle Scholar | 23769234PubMed |
[6] Molina J-M, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, et al On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. N Engl J Med 2015; 373 2237–46.
| On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial.Crossref | GoogleScholarGoogle Scholar | 26624850PubMed |
[7] Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367 423–34.
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.Crossref | GoogleScholarGoogle Scholar | 22784038PubMed |
[8] McCormack S, Dunn D, Desai M, Dolling DI, Mitzy G, Gilson R, et al Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. Lancet 2016; 387 53–60.
| Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study.Crossref | GoogleScholarGoogle Scholar | 26364263PubMed |
[9] Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363 2587–99.
| Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 21091279PubMed |
[10] Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV 2015; 2 e512–9.
| HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.Crossref | GoogleScholarGoogle Scholar | 26614965PubMed |
[11] Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open 2014; 4 e005717
| Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland.Crossref | GoogleScholarGoogle Scholar | 25412863PubMed |
[12] Saxton P, Giola M, Coughlan E, Rich J, Azariah S, Ludlam A, et al Implementing HIV pre-exposure prophylaxis (PrEP): let’s not get caught with our pants down. N Z Med J 2018; 131 64–73.
| 30161114PubMed |
[13] Rivet Amico K, Bekker L-G. Global PrEP roll-out: recommendations for programmatic success. Lancet HIV 2019; 6 e137–40.
| Global PrEP roll-out: recommendations for programmatic success.Crossref | GoogleScholarGoogle Scholar | 30660592PubMed |
[14] Wright E, Grulich A, Roy K, Boyd M, Cornelisse V, Russell D, et al Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad 2017; 3 168
| 28758027PubMed |
[15] World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations– 2016 update. Report No.: 9241511125. Geneva: WHO; 2016.
[16] Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018.
[17] AIDS Epidemiology Group. AIDS – New Zealand. Dunedin: Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago; 2018.
[18] Haddad N, Li J, Totten S, McGuire M. HIV in Canada—Surveillance Report, 2017. Can Commun Dis Rep 2018; 44 348–56.
| HIV in Canada—Surveillance Report, 2017.Crossref | GoogleScholarGoogle Scholar | 30906230PubMed |
[19] Nash S DS, Croxford S, Guerra L, Lowndes C, Connor N, Gill ON. Progress towards ending the HIV epidemic in the UK: 2018 report. London: Public Health England; 2018.
[20] Kirwan P, Chau C, Brown A, Gill O, Delpech V. HIV in the UK—2016 report. Contract No.: 6. London: Public Health England; 2016.
[21] New Zealand AIDS Foundation. Strategic Plan 2016–2019. Auckland: NZAF; 2016. Available online at: https://www.nzaf.org.nz/media/1259/161205_nzaf_strategic_plan_2016-2019.pdf
[22] CATIE. The epidemiology of HIV in Canada 2018. 2019. Available online at: https://www.catie.ca/sites/default/files/fs-epi-hiv-canada-EN-2018-09-06.pdf.
[23] Loos J, Nostlinger C, Reyniers T, Colebunders R, Jespers V, Manirankunda L, et al PrEP for African migrants in Europe? A research agenda. Lancet HIV 2016; 3 e505–7.
| PrEP for African migrants in Europe? A research agenda.Crossref | GoogleScholarGoogle Scholar | 27788864PubMed |
[24] Vuylsteke B, Reyniers T, Lucet C, Nostlinger C, Deblonde J, Libois A, et al High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports. Sex Health 2018; 16 80–3.
| High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports.Crossref | GoogleScholarGoogle Scholar |
[25] Kwakwa H, Wahome R.. Perceptions of HIV pre-exposure prophylaxis in African and Caribbean communities in urban United States. Sexually Transmitted Diseases 2014; 41 S123–S4.
| Perceptions of HIV pre-exposure prophylaxis in African and Caribbean communities in urban United States.Crossref | GoogleScholarGoogle Scholar |
[26] Ekong N, Braunholtz-Speight J, Mukelabai N, Evans A. Awareness of pre-exposure prophylaxis (PrEP) in the black and minority ethnic (BME) community: results of a questionnaire survey. HIV Med 2018; 19 S44–5.
[27] Okoro ON, Whitson SO. Sexual health, HIV care and pre-exposure prophylaxis in the African immigrant population: a needs assessment. J Immigr Minor Health 2019; 22 134–44.
| Sexual health, HIV care and pre-exposure prophylaxis in the African immigrant population: a needs assessment.Crossref | GoogleScholarGoogle Scholar |
[28] Witzel TC, Nutland W, Bourne A. What qualities in a potential HIV pre-exposure prophylaxis service are valued by black men who have sex with men in London? A qualitative acceptability study. Int J STD AIDS 2018; 29 760–5.
| What qualities in a potential HIV pre-exposure prophylaxis service are valued by black men who have sex with men in London? A qualitative acceptability study.Crossref | GoogleScholarGoogle Scholar | 29466919PubMed |
[29] Witzel TC, Nutland WR, Bourne AH. O02 What are the motivations and barriers to effective HIV pre-exposure prophylaxis (PREP) use for black men who have sex with men (BMSM) aged 18–45 in London? Results from a qualitative study. Sex Transm Infect 2017; 93 A1–A103.
[30] Mullens AB, Kelly J, Debattista J, Phillips TM, Gu Z, Siggins F. Exploring HIV risks, testing and prevention among sub-Saharan African community members in Australia. Int J Equity Health 2018; 17 62
| Exploring HIV risks, testing and prevention among sub-Saharan African community members in Australia.Crossref | GoogleScholarGoogle Scholar | 29784050PubMed |
[31] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6 e1000100
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.Crossref | GoogleScholarGoogle Scholar | 19621072PubMed |
[32] Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7 10
| Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.Crossref | GoogleScholarGoogle Scholar | 17302989PubMed |
[33] Programme CAS. CASP Qualitative Checklist. 2018. Available online at: https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf.
[34] Tate KJ, Newbury‐Birch D, McGeechan G. A systematic review of qualitative evidence of cancer patients’ attitudes to mindfulness. Eur J Cancer Care (Engl) 2018; 27 e12783
| A systematic review of qualitative evidence of cancer patients’ attitudes to mindfulness.Crossref | GoogleScholarGoogle Scholar |
[35] Joanna Briggs Institute. Critical appraisal checklist for analytical cross sectional studies. 2017. Available online at: https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_Sectional_Studies2017_0.pdf.
[36] Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 2008; 8 45
| Methods for the thematic synthesis of qualitative research in systematic reviews.Crossref | GoogleScholarGoogle Scholar | 18616818PubMed |
[37] Bearman M, Dawson P. Qualitative synthesis and systematic review in health professions education. Med Educ 2013; 47 252–60.
| Qualitative synthesis and systematic review in health professions education.Crossref | GoogleScholarGoogle Scholar | 23398011PubMed |
[38] Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3 77–101.
| Using thematic analysis in psychology.Crossref | GoogleScholarGoogle Scholar |
[39] Bazzi AR, Leech AA, Biancarelli DL, Sullivan M, Drainoni ML. Experiences using pre-exposure prophylaxis for safer conception among HIV serodiscordant heterosexual couples in the United States. AIDS Patient Care STDS 2017; 31 348–55.
| Experiences using pre-exposure prophylaxis for safer conception among HIV serodiscordant heterosexual couples in the United States.Crossref | GoogleScholarGoogle Scholar | 28719229PubMed |
[40] Gardezi F, Calzavara L, Husbands W, Tharao W, Lawson E, Myers T, et al Experiences of and responses to HIV among African and Caribbean communities in Toronto, Canada. AIDS Care 2008; 20 718–25.
| Experiences of and responses to HIV among African and Caribbean communities in Toronto, Canada.Crossref | GoogleScholarGoogle Scholar | 18576174PubMed |
[41] Okoro ON, Whitson SO. HIV risk and barriers to care for African-born immigrant women: a sociocultural outlook. Int J Women’s Health 2017; 9 421–9.
| HIV risk and barriers to care for African-born immigrant women: a sociocultural outlook.Crossref | GoogleScholarGoogle Scholar |
[42] Logie CH, Okumu M, Ryan S, Yehdego DM, Lee-Foon N. Adapting and pilot testing the Healthy Love HIV and sexually transmitted infection prevention intervention with African, Caribbean and Black women in community-based settings in Toronto, Canada. Int J STD AIDS 2018; 29 751–9.
| Adapting and pilot testing the Healthy Love HIV and sexually transmitted infection prevention intervention with African, Caribbean and Black women in community-based settings in Toronto, Canada.Crossref | GoogleScholarGoogle Scholar | 29439590PubMed |
[43] Australian Federation of AIDS Organisation. PrEP Fact Sheet: AFAO & ASHM; 2018. Available online at: https://www.afao.org.au/wp-content/uploads/2018/03/2335_afao_prep_fact_sheet_11-1.pdf.
[44] PrEP Access Now. PrEP Access Now: PrEPaccessNOW. 2018. Available online at: https://www.pan.org.au/prep-101.
